Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?

References

• WeinshenkerBGEbersGCThe natural history of multiple sclerosisCan J Neurol Sci1987142552613311324
   PubMed Web of Science ®Google Scholar
• WeinshenkerBGThe natural history of multiple sclerosisNeurol Clin1995131191467739500
   PubMed Web of Science ®Google Scholar
• [No authors listed]Interferon beta-1b is effective in relapsing–remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study GroupNeurology1993436556618469318
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III. multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology199545126812767617181
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDRudickRIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosisAnn Neurol1996392852948602746
   PubMed Web of Science ®Google Scholar
• [No authors listed]Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupLancet1998352149815049820297
   PubMed Web of Science ®Google Scholar
• [No authors listed]Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis GroupNeurology199545127712857617182
   PubMed Web of Science ®Google Scholar
• KapposLTraboulseeAConstantinescuCLong-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSNeurology20066794495317000959
   PubMed Web of Science ®Google Scholar
• JohnsonKPFordCCLisakRPWolinskyJSNeurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year dataActa Neurol Scand2005111424715595937
   PubMed Web of Science ®Google Scholar
• SorensenPSKoch-HenriksenNRavnborgMImmunomodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide surveyMult Scler20061225326416764337
   PubMed Web of Science ®Google Scholar
• [No authors listed]Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron Report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology199444153715408058168
   PubMed Web of Science ®Google Scholar
• PoserCMPatyDWScheinbergLNew diagnostic criteria for multiple sclerosis: guidelines for research protocolsAnn Neurol1983132272316847134
   PubMed Web of Science ®Google Scholar
• KurtzkeJFRating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)Neurology198333144414526685237
   PubMed Web of Science ®Google Scholar
• SyedRAMarkAACurrent approved options for treating patients with multiple sclerosisNeurology200463S8S14
   PubMed Web of Science ®Google Scholar
• NoseworthyJHEbersGCVandervoortMKFarquharREYetisirERobertsRThe impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trialNeurology19944416208290055
   PubMed Web of Science ®Google Scholar
• BencsikKFuvesiJFricska-NagyZShort communication: treatment of relapsing-remitting multiple sclerosis patients with IFN-beta1b: results of a 6-year follow-upJ Interferon Cytokine Res2006269610016487029
   PubMed Web of Science ®Google Scholar
• LimmrothVMalessaRZettlUKQuality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosisJ Neurol2007254677717273808
   PubMed Web of Science ®Google Scholar
• PanitchHGoodinDSFrancisGRandomized, comparative study of interferon β-1a treatment regimens in MS. The EVIDENCE trialNeurology2002591496150612451188
   PubMed Web of Science ®Google Scholar
• FreedmanMSLong-term follow-up of clinical trials of multiple sclerosis therapiesNeurology201176S26S3421205679
   PubMed Web of Science ®Google Scholar
• KremenchutzkyMRiceGPBaskervilleJWingerchukDMEbersGCThe natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the diseaseBrain200612958459416401620
   PubMed Web of Science ®Google Scholar
• MilaneseCLa MantiaLPalumboRA post-marketing study on interferon β 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patientsJ Neurol Neurosurg Psychiatry2003741689169214638892
   PubMed Web of Science ®Google Scholar
• MirallesAAFuentesBBarreiroPDiez-TejedorEComparative clinical efficacy analysis between interferon beta 1-b and interferon beta 1-aJ Neurol2000247III139
   Google Scholar
• ÖztekinNÖztekinMFAn open-label trial comparing the effects of IFNß-1a (Rebif), (Avonex), and IFNß-1b (Betaferon) on the relapse rate, lesion load on MRI and disease progression in patients with relapsing-remitting multiple sclerosis: results of 24 months of therapyMult Scler20017S96
   Google Scholar
• TrojanoMLiguoriMPaolicelliDInterferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern ItalyMult Scler2003945145714582768
   PubMed Web of Science ®Google Scholar
• MikolDDBarkhofFChangPComparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialLancet Neurol2008790391418789766
   PubMed Web of Science ®Google Scholar
• HaasJFirzlaffMTwenty-four-month comparison of immunomodulatory treatments – a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone)Eur J Neur200512425431
   Web of Science ®Google Scholar
• DurelliLVerdunEBarberoPEvery-other-day interferon beta-1b versus once-weekly interferon beta-1b for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN)Lancet20023591453146011988242
   PubMed Web of Science ®Google Scholar
• JacobsLDBeckRWSimonJHIntramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosisN Engl J Med200034389890411006365
   PubMed Web of Science ®Google Scholar
• KinkelRPKollmanCO’ConnorPIM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating eventNeurology20066667868416436649
   PubMed Web of Science ®Google Scholar
• ComiGFilippiMBarkhofFEffect of early interferon treatment on conversion to definite multiple sclerosis: a randomised studyLancet20013571576158211377645
   PubMed Web of Science ®Google Scholar
• KapposLPolmanCHFreedmanMSTreatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromesNeurology2006671242124916914693
   PubMed Web of Science ®Google Scholar
• BeiskeAGMyhrKMLipoatrophy: a non-reversible complication of subcutaneous interferon-beta 1a treatment of multiple sclerosisJ Neurol200625337737816502214
   PubMed Web of Science ®Google Scholar
• ConfavreuxCVukusicSAccumulation of irreversible disability in multiple sclerosis: from epidemiology to treatmentClin Neurol Neurosurg200610832733216413961
   PubMed Web of Science ®Google Scholar
• HutchinsonMPredicting and preventing the future: actively managing multiple sclerosisPract Neurol20099133143 discussion 14419448055
   PubMedGoogle Scholar
• LimmrothVPutzkiNKachuckNJThe interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combinationTher Adv Neurol Disord2011428129622010041
   PubMedGoogle Scholar
• WaubantEVukusicSGignouxLClinical characteristics of responders to interferon therapy for relapsing MSNeurology20036118418912874396
   PubMed Web of Science ®Google Scholar
• RíoJNosCTintoréMDefining the response to interferon-beta in relapsing-remitting multiple sclerosis patientsAnn Neurol20065934435216437558
   PubMed Web of Science ®Google Scholar
• PozziliCProsperiniLClinical markers of therapeutic response to disease modifying drugsNeurol Sci200829S211S21318690494
   PubMed Web of Science ®Google Scholar
• RíoJCastillóJRoviraAMeasures in the first year of therapy predict the response to interferon {beta} in MSMult Scler20091584885319542263
   PubMed Web of Science ®Google Scholar
• ProsperiniLGalloVPetsasNBorrielloGPozzilliCOne-year MRI scan predicts clinical response to interferon beta in multiple sclerosisEur J Neurol2009161202120919538207
   PubMed Web of Science ®Google Scholar
• CréangeADebouverieMJaillon-RivièreVHome administration of intravenous methylprednisolone for multiple sclerosis relapses: the experience of French multiple sclerosis networksMult Scler2009151085109119556312
   PubMed Web of Science ®Google Scholar